193
Views
20
CrossRef citations to date
0
Altmetric
BRIEF REPORTS

Unstable EEG-vigilance in patients with cancer-related fatigue (CRF) in comparison to healthy controls

, , , , , , & show all
Pages 146-152 | Received 25 Aug 2010, Accepted 02 Dec 2010, Published online: 19 Jan 2011
 

Abstract

Objectives. Cancer-related fatigue (CRF) is associated with tiredness and sleepiness. It remains unclear, whether such complaints are associated with neurophysiological signs of sleep proneness or a state of neurophysiological hyperarousal in which the patient finds it difficult to relax and to initiate sleep. Therefore the goal of this study is to compare the electroencephalographic (EEG)-vigilance regulation of patients with CRF and healthy controls. Methods. A 15-min resting EEG with eyes closed was recorded in 22 patients with CRF and 22 matched healthy controls. Consecutive 1-s segments were classified into seven different vigilance stages ranging from high alertness to relaxed wakefulness (stage 0, A1, A2, A3) and further on to drowsiness (B1, B2/3) and sleep onset (stage C). Results. Results showed that patients with CRF revealed a higher number of vigilance stages A3 (mean 15.26 vs. 6.67%, P = 0.004) dropped significantly earlier to vigilance levels A3 (drop after 130.8 vs. 533.3 s, P = 0.000) and B2/3&C (407.8 vs. 604.1 s, P = 0.035) and showed significantly more transitions between vigilance stages (46.0 vs. 31.1%, P = 0.003) in comparison to healthy controls. Conclusions. These findings suggest an unstable vigilance regulation in patients with CRF and provide a neurophysiological framework for the reported efficacy of psychostimulants in CRF.

Acknowledgements

We would like to thank Prof. Dr. Schwarz, who was engaged in the enrollment of the study. Prof. Schwarz died in 2009.

Statement of Interest

The research group received fees according to the German medical fee schedule for recording of clinical EEG for the CRF study population from Medice. Ulrich Hegerl has been participating in advisory boards of Lilly, Wyeth, Lundbeck and Sanofi-Aventis and received honoraria from Cephalon.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.